Newswise — AACC President-Elect Dr. David Grenache discusses what we know so far about the body’s immune response to COVID-19, and why the presence of antibodies to the novel coronavirus doesn’t yet tell us whether or not a person is immune.
Filters close
Showing results
11–20 of 4578
Released: 15-Jan-2021 1:30 PM EST
New England Journal of Medicine publishes COVID-19 treatment trial results
University of Texas at San AntonioA clinical trial involving COVID-19 patients hospitalized at UT Health San Antonio and University Health, among roughly 100 sites globally, found that a combination of the drugs baricitinib and remdesivir reduced time to recovery, according to results published Dec. 11 in the New England Journal of Medicine.
Released: 15-Jan-2021 12:40 PM EST
DNA test can quickly identify pneumonia in patients with severe COVID-19, aiding faster treatment
University of CambridgeResearchers have developed a DNA test to quickly identify secondary infections in COVID-19 patients, who have double the risk of developing pneumonia while on ventilation than non-COVID-19 patients.
Released: 15-Jan-2021 12:30 PM EST
Fight CRC To Present Research Findings on The Impact of COVID-19 on the Colorectal Cancer Community at 2021 GI ASCO
Fight Colorectal CancerFight Colorectal Cancer presents abstract at Gastrointestinal Cancer Symposium highlighting the need to address the barriers and opportunities for care within the colorectal cancer community during the COVID-19 pandemic
Released: 15-Jan-2021 12:25 PM EST
Technion to Award Honorary Doctorate to Pfizer CEO Dr. Albert Bourla
American Technion SocietyIsrael's Technion will award an honorary doctorate to Pfizer CEO and Chairman Dr. Albert Bourla, for leading the development of the novel vaccine against SARS-CoV-2, the virus that causes COVID-19. The honorary doctorate will be conferred at the Technion Board of Governors meeting in November 2021.
Released: 15-Jan-2021 11:30 AM EST
UW researchers develop tool to equitably distribute limited vaccines
University of Wisconsin-MadisonResearchers at the University of Wisconsin School of Medicine and Public Health and UW Health have developed a tool that incorporates a person’s age and socioeconomic status to prioritize vaccine distribution among people who otherwise share similar risks due to their jobs.
Released: 15-Jan-2021 11:20 AM EST
Will Covid-19 kill the high street once and for all?
University of SheffieldThe shift to home working during Covid-19, or ‘Zoomshock’, threatens the survival of local goods and services provided in city centres and business parks
14-Jan-2021 5:00 PM EST
AACI Partners With Federal Vaccine Panel to Promote Cancer Patient Health
Association of American Cancer Institutes (AACI)AACI was invited last summer to join the Vaccine Consultation Panel (VCP) alongside other leading health and science organizations in the U.S. Through the VCP, AACI has received periodic updates on the development and distribution of COVID-19 vaccines and participated in efforts to educate the cancer center community and the general public on the importance of widespread vaccine uptake.
Released: 15-Jan-2021 8:55 AM EST
The First Dose of the Pfizer Vaccine Gives About 50% COVID Protection, Not 91% Claimed by Those Who Want to Speed Up Immunization
NewswiseThe NEJM paper actually states that the efficacy between the first and second doses was found to be 52 percent when given 21 days apart. After the second dose, the efficacy raises to 95 percent.
Released: 15-Jan-2021 8:20 AM EST
Houston Methodist study finds males of all ages more affected by COVID-19 than females
Houston MethodistA new Houston Methodist study found males are more likely to test positive for COVID-19, have complications and die from the virus than females, independent of age. The peer-reviewed observational study appears in PLOS ONE, a multidisciplinary journal published by the Public Library of Science.
Released: 15-Jan-2021 8:20 AM EST
NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19
Front Line COVID-19 Critical Care Alliance (FLCCC Alliance)NIH Revises Treatment Guidelines for Ivermectin for the Treatment of COVID-19 Ivermectin is Now a Therapeutic Option for Doctors & Prescribers
Showing results
11–20 of 4578
RSS Feeds by Section